Tsujitani S, Watanabe A, Kakeji Y, Maehara Y, Tomoda H, Furusawa M, Sugimachi K
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Eur J Surg Oncol. 1991 Oct;17(5):526-9.
Seventeen patients with colorectal cancer metastatic to the liver underwent hepatic resection. For five we prescribed adjuvant therapy which included intraportal mitomycin C (MMC) and 5-fluorouracil (5-FU) and consecutive oral administrations of tegafur (N1-(2'-tetrahydrofuryl)-5-fluorouracil), in an attempt to reduce recurrences in the liver. Intraportal chemotherapy consisted of low-dosage, long-term 5-FU infusion, 40 days at 250 mg/day, and a 10 mg bolus injection of MMC at the start and the end of continuous 5-FU infusion. With regard to postoperative events in patients given the infusion therapy, there was no hepatotoxicity or hematologic toxicity, no mechanical complications and no pain or vomiting. Two of five patients given infusion therapy and six of 12 not given the therapy died within 5 years after surgery. There was recurrence in the liver in two patients given infusion therapy and in four not given the therapy. Although low-dosage, long-term intraportal chemotherapy is a safe treatment given hopefully to prevent hepatic recurrence, we found no beneficial effect.
17例发生肝转移的结直肠癌患者接受了肝切除术。其中5例患者接受了辅助治疗，包括门静脉内注射丝裂霉素C（MMC）和5-氟尿嘧啶（5-FU），并连续口服替加氟（N1-(2'-四氢呋喃基)-5-氟尿嘧啶），以试图减少肝脏复发。门静脉内化疗包括低剂量、长期输注5-FU，每天250mg，共40天，在连续5-FU输注开始和结束时分别静脉推注10mg MMC。关于接受输注治疗患者的术后情况，未出现肝毒性或血液学毒性，未发生机械性并发症，也没有疼痛或呕吐。接受输注治疗的5例患者中有2例，未接受该治疗的12例患者中有6例在术后5年内死亡。接受输注治疗的患者中有2例肝脏复发，未接受治疗的患者中有4例复发。尽管低剂量、长期门静脉内化疗是一种有望预防肝复发的安全治疗方法，但我们未发现其有益效果。
